сгенерировать QR код
Открытый доступ
Только для подписчиков
Возрастные и гендерные аспекты болезни Паркинсона
https://doi.org/10.30629/0023-2149-2025-103-1-13-22
Аннотация
Болезнь Паркинсона (БП) по-разному влияет на мужчин и женщин, обусловливая уникальные вызовы и подходы в ее лечении. У мужчин риск развития БП в два раза выше, чем у женщин, но у женщин наблюдаются более быстрое прогрессирование заболевания и более высокий уровень смертности. Кроме того, моторные и немоторные симптомы, реакция на лечение и факторы риска различаются у мужчин и женщин. Эти различия поддерживают гипотезу о том, что патогенез заболевания может включать различные механизмы у пациентов разного пола или одни и те же механизмы, проявляющиеся по-разному. В настоящем обзоре обобщены современные знания о гендерных различиях в клинических проявлениях БП, факторах риска, ответе на лечение и патофизиологических механизмах заболевания. Понимание того, как патология по-разному влияет на мужчин и женщин, может способствовать разработке индивидуализированных вмешательств и инновационных программ, отвечающих различным потребностям пациентов обоих полов, улучшая тем самым качество ухода за ними.
Ключевые слова
При поддержке: Исследование не имело спонсорской поддержки.
Об авторах
Ф. А. Юсупов
Ошский государственный университет
Кыргызстан
Кыргызстан
Юсупов Фуркат Абдулахатович — д-р мед. наук, профессор медицинского факультета
Ош
И. Т. Ыдырысов
Ошский государственный университет
Кыргызстан
Кыргызстан
Ыдырысов Исматилла Токтосунович — д-р мед. наук, профессор медицинского факультета
Ош
М. Ш. Абдыкадыров
Ошский государственный университет
Кыргызстан
Кыргызстан
Абдыкадыров Мухаммадюсуф Шкуратович — аспирант медицинского факультета
Ош
Т. Ф. Юсупова
Ошский государственный университет
Кыргызстан
Кыргызстан
Юсупова Турсуной Фуркатовна — медицинский факультет
Ош
Список литературы
1. Юсупов Ф.А., Юлдашев А.А., Нурматов Т.А. Биомаркеры ранней диагностики болезни Паркинсона. Бюллетень науки и практики. 2024;10(7):309–323. DOI: 10.33619/2414-2948/104/33
2. Helle J. (2014). Evidence for gender differences in cognition, emotion and quality of life in Parkinson’s disease? Aging and Disease. 2013;5(1):63–75. DOI: 10.14336/ad.2014.050063
3. Picillo M., Erro R., Amboni M., Longo K., Vitale C., Moccia M.et al. Gender differences in non-motor symptoms in early Parkinson’s disease: A 2-years follow-up study on previously untreated patients. Parkinsonism and amp; Related Disorders, 2014;20(8):850–854. DOI: 10.1016/j.parkreldis.2014.04.023
4. Baldereschi M., Di Carlo A., Rocca W.A., Vanni P., Maggi S., Perissinotto E., Grigoletto F., Amaducci L., & Inzitari, D. Parkinson’s disease and parkinsonism in a longitudinal study. Neurology, 2000;55(9):1358–1363. DOI: 10.1212/wnl.55.9.1358
5. Solla P., Cannas A., Ibba F.C., Loi F., Corona M., Orofi no G., Marrosu M.G., & Marrosu F. (). Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson’s disease. Journal of the Neurological Sciences. 2012;323(1–2):33– 39. DOI: 10.1016/j.jns.2012.07.026
6. Dahodwala N., Shah K., He Y., Wu S. S., Schmidt P., Cubillos F., & Willis A.W. (2018). Sex disparities in access to caregiving in Parkinson disease. Neurology, 2017;90(1):e48–e54. DOI: 10.1212/wnl.0000000000004764
7. Georgiev D., Hamberg K., Hariz M., Forsgren L., Hariz G.-M. Gender differences in Parkinson’s disease: A clinical perspective. Acta Neurologica Scandinavica. 2017;136(6):570–584. Portico. DOI: 10.1111/ane.12796
8. Willis A.W., Schootman M., Evanoff B.A., Perlmutter J.S., Racette B.A. Neurologist care in Parkinson disease. Neurology. 2011;77(9):851–857. DOI: 10.1212/wnl.0b013e31822c9123
9. Richter D., Bartig D., Muhlack S., Hartelt E., Scherbaum R., Katsanos A.H. et al. Dynamics of Parkinson’s disease multimodal complex treatment in germany from 2010–2016: patient characteristics, access to treatment, and formation of regional centers. Cells. 2019;8(2):151. DOI: 10.3390/cells8020151
10. Wirtz V.J. Priority medicines for Europe and the World: setting a public-health-based medicines development agenda. Journal of Pharmaceutical Policy and Practice. 2015;8(S1). DOI: 10.1186/2052-3211-8-s1-k4
11. Hirsch L., Jette N., Frolkis A., Steeves T., Pringsheim T. The Incidence of Parkinson’s Disease: A Systematic Review and MetaAnalysis. Neuroepidemiology. 2016;46(4):292–300. Portico. DOI: 10.1159/000445751
12. Savica R., Grossardt B.R., Rocca W.A., Bower J.H. Parkinson disease with and without Dementia: A prevalence study and future projections. Movement Disorders. 2018;33(4):537–543. Portico. DOI: 10.1002/mds.27277
13. Larsson V., Torisson G., Londos E. Relative survival in patients with dementia with Lewy bodies and Parkinson’s disease dementia. PLOS ONE. 2018;13(8):e0202044. DOI: 10.1371/journal.pone.0202044
14. Park K., Oeda T., Kohsaka M., Tomita S., Umemura A., & Sawada H. (). Low body mass index and life prognosis in Parkinson’s disease. Parkinsonism and Related Disorders, 2018;55:81–85. DOI: 10.1016/j.parkreldis.2018.05.011
15. Baba Y., Putzke J.D., Whaley N.R., Wszolek Z.K., & Uitti R.J. (). Gender and the Parkinson’s disease phenotype. Journal of Neurology. 2005;252(10):1201–1205. DOI: 10.1007/s00415-005-0835-7
16. Haaxma C.A., Bloem B.R., Borm G.F., Oyen W.J.G., Leenders K.L. et al. Gender differences in Parkinson’s disease. Journal of Neu rology, Neurosurgery and Psychiatry. 2007;78(8):819–824. DOI: 10.1136/jnnp.2006.103788
17. Colombo D., Abbruzzese G., Antonini A., Barone P., Bellia G., Franconi F. et al. The “Gender Factor” in wearing‐off among patients with Parkinson’s disease: a post hoc analysis of DEEP Study. The Scientific World Journal. 2015;1. DOI: 10.1155/2015/787451
18. Kim R., Lee, J., KimY., Kim A., Jang M., Kim H.-J. et al. (). Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson’s disease: An analysis of the PPMI cohort. Parkinsonism and Related Disorders. 2018;51:49–54. DOI: 10.1016/j.parkreldis.2018.02.047
19. Parashos S.A., Bloem B.R., Browner N.M., Giladi N., Gurevich T., Hausdorff J.M. et al. What predicts falls in Parkinson disease? Neurology Clinical Practice. 2018;8(3):214–222. DOI: 10.1212/cpj.0000000000000461
20. Ou R., Liu H., Hou Y., Song W., Cao B., Wei Q.et al. Predictors of camptocormia in patients with Parkinson’s disease: A prospective study from southwest China. Parkinsonism & Related Disorders. 2018;52:69–75. DOI: 10.1016/j.parkreldis.2018.03.020
21. Martinez-Martin P., Pecurariu C. F., Odin P., Hilten J.J., Antonini A., Rojo-Abuin J.M. et al. Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. Journal of Neurology. 2012;259(8):1639–1647. DOI: 10.1007/s00415-011-6392-3
22. Silverdale M.A., Kobylecki C., Kass-Iliyya L., Martinez-Martin P., Lawton M., Cotterill S. et al. A detailed clinical study of pain in 1957 participants with early/moderate Parkinson’s disease. Parkinsonism & Related Disorders. 2018;56:27–32. DOI: 10.1016/j.parkreldis.2018.06.001
23. Houser M.C., Chang J., Factor S.A., Molho E.S., Zabetian C.P., Hill‐Burns E.M.et al. Stool immune profiles evince gastrointestinal inflammation in Parkinson’s disease. Movement Disorders. 2018;33(5):793–804. Portico. DOI: 10.1002/mds.27326
24. Nienstedt J. C., Bihler M., Niessen A., Plaetke R., Pötter‐Nerger M., Gerloff C., Buhmann C., Pflug C. Predictive clinical factors for penetration and aspiration in Parkinson’s disease. Neurogastroenterology & Motility. 2018;31(3). DOI: 10.1111/nmo.13524
25. Mao C.J., Xiong Y.T., Wang F., Yang Y.P., Yuan, W., Zhu C.et al. Motor subtypes and other risk factors associated with drooling in Parkinson’s disease patients. Acta Neurologica Scandinavica. 2018;137(5):509–514. DOI: 10.1111/ane.12893
26. Cholerton B., Johnson C.O., Fish B., Quinn J.F., Chung K.A., Peterson-Hiller A.L. et al. Sex differences in progression to mild cognitive impairment and dementia in Parkinson’s disease. Parkinsonism & Related Disorders. 2018;50:29–36. DOI: 10.1016/j.parkreldis.2018.02.007
27. Lin S.-J., Baumeister, T.R., Garg S., McKeown M.J. Cognitive Profiles and Hub Vulnerability in Parkinson’s Disease. Frontiers in Neurology. 2018;9. DOI: 10.3389/fneur.2018.00482
28. Broen M.P.G., Leentjens A.F.G., Hinkle J.T., Moonen A.J.H., Kuijf M.L., Fischer N.M.et al. Clinical markers of anxiety subtypes in Parkinson disease. Journal of Geriatric Psychiatry and Neurology. 2018;31(2):55–62. DOI: 10.1177/0891988718757369
29. Bhattacharjee S. Impulse control disorders in Parkinson’s disease: Review of pathophysiology, epidemiology, clinical features, management, and future challenges. Neurology India. 2018;66(4):967. DOI: 10.4103/0028-3886.237019
30. Buhmann C., Dogac S., Vettorazzi E., Hidding U., Gerloff C., & Jürgens T.P. The impact of Parkinson disease on patients’ sexuality and relationship. Journal of Neural Transmission. 2016;124(8):983–996. DOI: 10.1007/s00702-016-1649-8
31. Heller J., Mirzazade S., Romanzetti S., Habel U., Derntl B., Freitag N.M. et al. Impact of gender and genetics on emotion processing in Parkinson’s disease — A multimodal study. NeuroImage: Clinical. 2018;18:305–314. DOI: 10.1016/j.nicl.2018.01.034
32. Zhou J., Zhang J., Li Y., Du L., Li Z., Lei F. et al. Gender differences in REM sleep behavior disorder: a clinical and polysomnographic study in China. Sleep Medicine. 2015;16(3):414–418. DOI: 10.1016/j.sleep.2014.10.020
33. Haba-Rubio J., Frauscher B., Marques-Vidal P., Toriel J., Tobback N., Andries D.et al. Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population. Sleep. 2017;41(2). DOI: 10.1093/sleep/zsx197
34. Ophey A., Eggers C., Dano R., Timmermann L., Kalbe E. Health-related quality of life subdomains in patients with Parkinson’s disease: the role of gender. Parkinson’s Disease. 2018:1–9. DOI: 10.1155/2018/6532320
35. Balzer-Geldsetzer M., Klotsche J., Dodel R., Riedel O. Quality of life in a German cohort of Parkinson’s patients assessed with three different measures. Journal of Neurology. 2018;265(11):2713–2722. DOI: 10.1007/s00415-018-9047-9
36. Buczak-Stec E.W., König H.-H., Hajek A. Impact of Incident Parkinson’s Disease on Satisfaction With Life. Frontiers in Neurology. 2018;9. DOI: 10.3389/fneur.2018.00589
37. Heinzel S., Kasten M., Behnke S., Vollstedt E., Klein C., Hagenah J. et al. Age‐ and sex‐related heterogeneity in prodromal Parkinson’s disease. Movement Disorders. 2018;33(6):1025–1027. Portico. DOI: 10.1002/mds.27349
38. Savica R., Rocca W.A., Ahlskog J.E. When does Parkinson disease start? Archives of Neurology. 2010;67(7). DOI: 10.1001/archneurol.2010.135
39. O’Reilly E.J., Gao X., Weisskopf M.G., Chen H., Schwarzschild M.A., Spiegelman D., Ascherio A. Plasma urate and Parkinson’s disease in women. American Journal of Epidemiology. 2010;172(6):666–670. DOI: 10.1093/aje/kwq195
40. Cortese M., Riise T., Engeland A., Ascherio A., Bjørnevik K. Urate and the risk of Parkinson’s disease in men and women. Parkinsonism and Related Disorders. 2018;52:76–82. DOI: 10.1016/j.parkreldis.2018.03.026
41. Lee Y., Park Y.-H., Lee J.J., Sohn Y.H., Lee J.-M., Lee P.H. Gender-specificeffect of uricacid on resting-state functional networks in de novo Parkinson’s disease. Parkinsonism and Related Disorders. 2018;52:49–54. DOI: 10.1016/j.parkreldis.2018.03.023
42. Baksh R., Macklin E.A., Logan R., Zorlu M.M., Xia N., Crotty G.F. et al. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Annals of Neurology. 2019;85(4):593–599. Portico. DOI: 10.1002/ana.25436
43. Migdalska‐Richards A., Schapira, A.V. The relationship between glucocerebrosidase mutations and Parkinson disease. Journal of Neurochemistry. 2016;139(S1):77–90. Portico. DOI: 10.1111/jnc.13385
44. Liu L., Xiong N., Zhang P., Chen C., Huang J., Zhang G. et al. Genetic variants in GAPDH confer susceptibility to sporadic Parkinson’s disease in a chinese han population. PLOS ONE. 2015;10(8):e0135425. DOI: 10.1371/journal.pone.0135425
45. Alcalay R.N., Wolf P., Levy O.A., Kang U.J., Waters C. et al. Alpha galactosidase A activity in Parkinson’s disease. Neurobiology of Disease. 2018;112, 85–90. DOI: 10.1016/j.nbd.2018.01.012
46. Ping Z., Xiaomu W., Xufang, X., Wenfeng C., Liang S., Tao W. GAPDH rs1136666 SNP indicates a high risk of Parkinson’s disease. Neuroscience Letters. 2018;685:55–62. DOI: 10.1016/j.neulet.2018.06.011
47. Hemmerle A.M., Herman J.P., Seroogy K.B. Stress, depression and Parkinson’s disease. Experimental Neurology. 2012;233(1):79–86. DOI: 10.1016/j.expneurol.2011.09.035
48. Sieurin J., Andel R., Tillander A., Valdes E.G., Pedersen N.L., Wirdefeldt K. Occupational stress and risk for Parkinson’s disease: A nationwide cohort study. Movement Disorders. 2018;33(9):1456–1464. DOI: 10.1002/mds.27439
49. Teschke K., Marion S.A., Tsui J.K.C., Shen H., Rugbjerg K., Harris M.A. Parkinson’s Disease and Occupation: Differences in Associations by Case Identification Method Suggest Referral Bias. American Journal of Industrial Medicine. 2013;57(2):163–171. DOI: 10.1002/ajim.22272
50. Vlaar T., Kab S., Schwaab Y., Fréry N., Elbaz A., Moisan F. Association of Parkinson’s disease with industry sectors: a French nationwide incidence study. European Journal of Epidemiology. 2018;33(11):1101–1111. DOI: 10.1007/s10654-018-0399-3
51. Rozani V., Gurevich T., Giladi N., El‐Ad B., Tsamir J., Hemo B., Peretz C. Higher serum cholesterol and decreased Parkinson’s disease risk: A statin‐free cohort study. Movement Disorders. 2018;33(8):1298–1305. DOI: 10.1002/mds.27413
52. Rafferty M.R., Schmidt P.N., Luo S. T., Li K., Marras C., Davis T.L. et al. Regular Exercise, Quality of Life, and Mobility in Parkinson’s Disease: A Longitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative Data. Journal of Parkinson’s Disease. 2017;7(1):193–202. DOI: 10.3233/jpd-160912
53. Mantri S., Fullard M.E., Duda J.E., Morley J.F. Physical Activity in Early Parkinson Disease. Journal of Parkinson’s Disease. 2018;8(1):107–111. DOI: 10.3233/jpd-171218
54. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa‐induced dyskinesias. Movement Disorders. 2007;22(10):1379–1389. DOI: 10.1002/mds.21475
55. Martinelli P., Contin M., Scaglione C., Riva R., Albani F., Baruzzi A. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Neurological Sciences. 2003;24(3):192–193. DOI: 10.1007/s10072-003-0125-z
56. Goudreau J.L., Maraganore D.M., Farrer M.J., Lesnick T.G., Singleton A.B., Bower J.H. et al. Case‐Control study of dopamine transporter‐1, monoamine oxidase‐B, and catechol‐O‐methyl transferase polymorphisms in Parkinson’s disease. Movement Disorders. 2002;17(6):1305–1311. DOI: 10.1002/mds.10268
57. Sampaio T.F., dos Santos E.U.D., de Lima G.D.C., dos Anjos R.S.G., da Silva R.C., Asano A.G.C. et al. MAO‐Band COMT genetic variations associated with levodopa treatment response in patients with Parkinson’s disease. The Journal of Clinical Pharmacology. 2018;58(7):920–926. DOI: 10.1002/jcph.1096
58. Wang J., Liu Z.-L., Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology. 2001;56(12):1757–1759. DOI: 10.1212/wnl.56.12.1757
59. Kaiser R., Hofer A., Grapengiesser A., Gasser T., Kupsch A., Roots I., Brockmö ller J. l-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology. 2003;60(11):1750– 1755. DOI: 10.1212/01.wnl.0000068009.32067.a1
60. dos Santos E.U.D., Sampaio T.F., Tenório dos Santos A.D., Bezerra Leite F.C., da Silva R.C., Crovella S. et al. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson’s disease. Journal of Pharmacy and Pharmacology. 2018;71(2):206–212. DOI: 10.1111/jphp.13031
61. Marras C., Austin P.C., Bronskill S.E., Diong C., Rochon P.A. Antipsychotic Drug Dispensing in Older Adults With Parkinsonism. The American Journal of Geriatric Psychiatry. 2018;26(12):1244–1257. DOI: 10.1016/j.jagp.2018.08.003
62. Drummond N., McCleary L., Garcia L., McGilton K., Molnar F., Dalziel W. et al. Assessing determinants of perceived quality in transi tions for people with dementia: a prospective observational study. Canadian Geriatrics Journal. 2019;22(1):13–22. DOI: 10.5770/cgj.22.332
63. Roediger J., Artusi C.A., Romagnolo A., Boyne P., Zibetti M., Lopiano L. et al. Effect of subthalamic deep brain stimulation on posture in Parkinson’s disease: A blind computerized analysis. Parkinsonism and Related Disorders. 2019;62:122–127. DOI: 10.1016/j.parkreldis.2019.01.003
64. Hariz G.-M., Limousin P., Zrinzo L., Tripoliti E., Aviles-Olmos I., Jahanshahi M., Hamberg K., Foltynie T. Gender differences in quality of life following subthalamic stimulation for Parkinson’s disease. Acta Neurologica Scandinavica. 2013;128(4):281–285. DOI: 10.1111/ane.12127
65. Gatto N.M., Deapen D., Stoyanoff, S., PinderR., Narayan S., Bordelon Y., Ritz B. Lifetime exposure to estrogens and Parkinson’s disease in California teachers. Parkinsonism & Related Disorders. 2014;20(11):1149–1156. DOI: 10.1016/j.parkreldis.2014.08.003
66. Nicoletti A., Arabia G., Pugliese P., Nicoletti G., Torchia G., Condino F.et al. Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia. Clinical Neuropharmacology. 2007;30(5):276–280. DOI: 10.1097/wnf.0b013e318050c9f9
67. Adams C., Kumar R. The effect of estrogen in a man with Parkinson’s disease and a review of its therapeutic potential. International Journal of Neuroscience. 2013;123(10):741–742. DOI: 10.3109/00207454.2013.797903
68. Lobo R.A. Hormone-replacement therapy: current thinking. Nature Reviews Endocrinology. 2016;13(4):220–231. DOI: 10.1038/nrendo.2016.164
69. Arnott J., Martinkovich S., Planey S.L., Shah D. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clinical Interventions in Aging. 2014;9:1437. DOI: 10.2147/cia.s66690
70. Jacobsen D.E., Melis R.J.F., Verhaar H.J.J., Olde Rikkert M.G.M. Ralo xifene and Tibolone in Elderly Women: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial. Journal of the American Medical Directors Association. 2012;13(2):189.e1-189. e7. DOI: 10.1016/j.jamda.2011.05.005
71. Goekoop R., Barkhof F., Duschek E.J.J., Netelenbos C., Knol D.L., Scheltens P., Rombouts S.A. Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI Study in Healthy Elderly Males. Neuropsychopharmacology. 2005;31(7):1508–1518. DOI: 10.1038/sj.npp.1300956
72. Luchett S., Bossers K., Frajese G.V., Swaab D.F. Neurosteroid Biosynthetic Pathway Changes in Substantia Nigra and Caudate Nucleus in Parkinson’s Disease. Brain Pathology. 2010;20(5):945–951. Portico. DOI: 10.1111/j.1750-3639.2010.00396.x
73. Paba S., Frau R., C. Godar S., Devoto P., Marrosu F., Bortolato M. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. Current Pharmaceutical Design. 2011;17(2):151–167. DOI: 10.2174/138161211795049589
74. Frau R., Savoia P., Fanni S., Fiorentini C., Fidalgo C., Tronci E.et al. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson’s disease. Experimental Neurology. 2017;291, 1–7. DOI: 10.1016/j.expneurol.2017.01.012
75. Simunovic F., Yi M., Wang Y., Stephens R., Sonntag K.C. Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. PLoS ONE. 2010;5(1):e8856. DOI: 10.1371/journal.pone.0008856
76. Cullity E.R., Madsen H.B., Perry C.J., Kim J.H. Postnatal developmental trajectory of dopamine receptor 1 and 2 expression in cortical and striatal brain regions. Journal of Comparative Neurology. 2018;527(6):1039–1055. DOI: 10.1002/cne.24574
77. Bispo J.M.M., Melo J.E.C., Gois A.M., Leal P.C., Lins,L.C.R.F., Souza M.F. et al. Sex differences in the progressive model of parkinsonism induced by reserpine in rats. Behavioural Brain Research. 2019;363, 23–29. DOI: 10.1016/j.bbr.2019.01.041
78. Costa G., Porceddu P.F., Serra M., Casu M.A., Schiano V., Napolitano F. et al. Lack of Rhes Increases MDMA-induced neuroinflammation and dopamine neuron degeneration: role of gender and age. International Journal of Molecular Sciences. 2019;20(7):1556. DOI: 10.3390/ijms20071556
79. Seyfried T.N., Choi H., Chevalier A., Hogan D., Akgoc Z., Schneider J.S. Sex-related abnormalities in substantia nigra lipids in Parkinson’s disease. ASN Neuro. 2018;10(1):175909141878188. DOI: 10.1177/1759091418781889
80. Marin R., Diaz M. Estrogen interactions with lipid rafts related to neuroprotection. Impact of brain ageing and menopause. Frontiers in Neuroscience. 2018;12:128 DOI: 10.3389/fnins.2018.00128
81. Song Z., Yang H., Peckham E.M., Becker J.B. Estradiol-induced potentiation of dopamine release in dorsal striatum following amphetamine administration requires estradiol receptors and mGlu5. Eneuro. 2019;6(1):ENEURO.0446-18.2019. DOI: 10.1523/eneuro.0446-18.2019
82. Conway S.M., Puttick D., Russell S., Potter D., Roitman M.F., Chartoff E.H. Females are less sensitive than males to the motivational- and dopamine-suppressing effects of kappa opioid receptor activation. Neuropharmacology. 2019;146:231–241. DOI: 10.1016/j.neuropharm.2018.12.002
83. Palmer A. L., Ousman, S. S. Astrocytes and aging. Frontiers in aging. Neuroscience. 2018;10:337. DOI: 10.3389/fnagi.2018.00337
84. Villa A., Gelosa P., Castiglioni L., Cimino M., Rizzi N., Pepe G. et al. Sex-specific features of microglia from adult mice. Cell Reports. 2018;23(12):3501–3511. DOI: 10.1016/j.celrep.2018.05.048
85. Hanamsagar, R., Alter M.D., Block C.S., Sullivan H., Bolton J.L., Bilbo S.D. Generation of a microglial developmental index in mice and in humans reveals a sex difference in maturation and immune reactivity. Glia. 2017;65(9):1504–1520. Portico. DOI: 10.1002/glia.23176
86. Lenz K.M., Nugent B.M., Haliyur R., McCarthy M.M. Microglia Are Essential to Masculinization of Brain and Behavior. The Journal of Neuroscience. 2013;33(7):2761–2772. DOI: 10.1523/jneurosci.1268-12.2013
87. Guan J., Yang B., Fan Y., Zhang J. GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease. Neuroimmunomodulation. 2017:24(1):60–66. DOI: 10.1159/000478908
88. Santos-Galindo M., Acaz-Fonseca E., Bellini M.J., Garcia-Segura L.M. Sex differences in the inflammatory response of primary astrocytes to lipopolysaccharide. Biology of Sex Differences. 2011;2(7). DOI: 10.1186/2042-6410-2-7
89. Jaber S.M., Bordt E.A., Bhatt N.M., Lewis D.M., Gerecht S., Fiskum G., Polster B.M. Sex differences in the mitochondrial bioenergetics of astrocytes but not microglia at a physiologically relevant brain oxygen tension. Neurochemistry International. 2018;117, 82–90. DOI: 10.1016/j.neuint.2017.09.003
90. Martin-Jiménez C., Gaitán-Vaca D.M., Areiza N., Echeverria V., Ashraf G.M., González J. et al. Astrocytes mediate protective actions of estrogenic compounds after traumatic brain injury. Neuroendocrinology. 2018;108(2):142–160. DOI: 10.1159/000495078
91. Yun J., Yeo I.J., Hwang C.J., Choi D.-Y., Im H.-S., Kim J.Y. et al. Estrogen deficiency exacerbates Aβ-induced memory impairment through enhancement of neuroinflammation, amyloidogenesis and NF-ĸB activation in ovariectomized mice. Brain, Behavior, and Immunity. 2018;73:282–293. DOI: 10.1016/j.bbi.2018.05.013
92. Chamniansawat S., Sawatdiyaphanon C. Age-Related Memory Impairment Associated With Decreased Endogenous Estradiol in the Hippocampus of Female Rats. International Journal of Toxicology. 2018:37(3):207–215. DOI: 10.1177/1091581818761653
Рецензия
Для цитирования:
Юсупов Ф.А., Ыдырысов И.Т., Абдыкадыров М.Ш., Юсупова Т.Ф. Возрастные и гендерные аспекты болезни Паркинсона. Клиническая медицина. 2025;103(1):13-22. https://doi.org/10.30629/0023-2149-2025-103-1-13-22
For citation:
Yusupov F.A., Ydyrysov I.T., Abdykadyrov M.Sh., Yusupova T.F. Age and gender aspects of parkinson's disease. Clinical Medicine (Russian Journal). 2025;103(1):13-22. (In Russ.) https://doi.org/10.30629/0023-2149-2025-103-1-13-22
Просмотров:
162
Послать статью по эл. почте 